# Pericytes: jack-of-all-trades in cancer-related inflammation

**Authors:** Marianna Moro, Federica Carolina Balestrero, Ambra A. Grolla

PMC · DOI: 10.3389/fphar.2024.1426033 · 2024-07-17

## TL;DR

This review explores how pericytes, once thought to be just support cells, play a key role in cancer-related inflammation and tumor progression by interacting with immune cells.

## Contribution

The paper highlights the novel roles of pericytes in cancer, particularly their involvement in immune cell interactions and tumor metastasis.

## Key findings

- Pericytes actively participate in immune cell transmigration into blood vessels.
- Pericytes contribute to an immunosuppressive environment in various cancers.
- Pericytes influence tumor reprogramming and pre-metastatic niche formation.

## Abstract

Pericytes, recognized as mural cells, have long been described as components involved in blood vessel formation, playing a mere supporting role for endothelial cells (ECs). Emerging evidence strongly suggests their multifaceted roles in tissues and organs. Indeed, pericytes exhibit a remarkable ability to anticipate endothelial cell behavior and adapt their functions based on the specific cells they interact with. Pericytes can be activated by pro-inflammatory stimuli and crosstalk with immune cells, actively participating in their transmigration into blood vessels. Moreover, they can influence the immune response, often sustaining an immunosuppressive phenotype in most of the cancer types studied. In this review, we concentrate on the intricate crosstalk between pericytes and immune cells in cancer, highlighting the primary evidence regarding pericyte involvement in primary tumor mass dynamics, their contributions to tumor reprogramming for invasion and migration of malignant cells, and their role in the formation of pre-metastatic niches. Finally, we explored recent and emerging pharmacological approaches aimed at vascular normalization, including novel strategies to enhance the efficacy of immunotherapy through combined use with anti-angiogenic drugs.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** inflammation (MESH:D007249), cancer (MESH:D009369)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11288921/full.md

---
Source: https://tomesphere.com/paper/PMC11288921